19 completed, 6 withdrawn, 3 unknown, 2 terminated. 32 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 32 | Completed 19, Withdrawn 6, Unknown 3, Terminated 2, Enrolling by invitation 1, Recruiting 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade Ondansetron every 3 weeks, Aprepitant, Dexamethasone - Nausea With Vomiting Chemotherapy-Induced | Not applicable | Recruiting | Hubei Cancer Hospital | 98 | 2023-12-01 | 2024-02-29 |
| Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention fosaprepitant, normal saline - Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures | Not applicable | Enrolling by invitation | Samsung Medical Center | 144 | 2023-08-18 | 2025-03-30 |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients fosaprepitant, aprepitant, Granisetron plus dexamethasone - Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients | Not applicable | Unknown | Shanghai Children's Medical Center | 120 | 2021-05-01 | 2021-05-10 |
| Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. Desloratadine 5 mg, Aprepitant 125 mg, Ketotifen 1 MG - Pruritus | Not applicable | Completed | Universitaire Ziekenhuizen KU Leuven | 13 | 2019-06-11 | 2020-05-27 |
| Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email - Postoperative Nausea and Vomiting | Not applicable | Completed | Vanderbilt University | 27034 | 2016-07-01 | 2019-03-07 |
| Aprepitant to Mitigate Opioids' Cognitive Side Effects Aprepitant, Placebo - Cognitive Dysfunction | Not applicable | Unknown | University of Arizona | 50 | 2014-10-01 | 2015-06-02 |
| Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant aprepitant, palonosetron, Ramosetron - Postoperative Nausea and Vomiting | Not applicable | Completed | Kyungpook National University Hospital | 88 | 2014-07-01 | 2017-04-25 |
| Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure Placebo, Sitagliptin, Aprepitant - Type 2 Diabetes Mellitus, Hypertension | Not applicable | Completed | Vanderbilt University | 106 | 2014-06-01 | 2022-03-02 |
| Developing Individualized Strategies to Prevent Nausea and Vomiting Ondansetron, Lorazepam, Aprepitant - Postoperative Nausea and Vomiting, Genetic Polymorphisms | Not applicable | Withdrawn | University of California, San Francisco | 2013-11-01 | 2013-11-14 | |
| Differentiating the Effects of Substance P and Beta-endorphin Aprepitant, Placebo - Chronic Obstructive Pulmonary Disease | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 10 | 2013-07-01 | 2018-10-30 |
| Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy fosaprepitant dimeglumine - Gastrointestinal Cancer, Nausea Post Chemotherapy | Not applicable | Completed | Philip Philip | 30 | 2012-06-01 | 2021-04-08 |
| The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing aprepitant, placebo - Chronic Obstructive Pulmonary Disease | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 16 | 2012-04-01 | 2013-07-19 |
| Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP Standard anti-emetics in conjunction with R-CHOP - Lymphoma, Non-Hodgkin | Not applicable | Withdrawn | Australasian Leukaemia and Lymphoma Group | 2012-01-01 | 2024-08-07 | |
| Comparison of Adding EMEND to PONV/PDNV Treatment Regimen aprepitant - Postoperative Nausea and Vomiting | Not applicable | Withdrawn | University of Nebraska | 2011-09-01 | 2024-08-30 | |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial Aprepitant / Fosaprepitant - Colorectal Cancer | Not applicable | Completed | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | 413 | 2011-04-01 | 2021-02-26 |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) aprepitant, palonosetron hydrochloride, ondansetron - Malignant Neoplasm | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 40 | 2011-01-01 | 2013-11-07 |
| Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer Aprepitant - Ovarian Cancer | Not applicable | Withdrawn | NYU Langone Health | 2010-12-01 | 2015-03-18 | |
| Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients Aprepitant, Aprepitant placebo - Nausea, Vomiting | Not applicable | Completed | University of Pennsylvania | 125 | 2010-05-01 | 2012-02-16 |
| Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy Aprepitant - Postoperative Nausea and Vomiting | Not applicable | Completed | Gachon University Gil Medical Center | 150 | 2010-03-01 | 2011-09-26 |
Showing 20 of 32. Sign in to see all of them.
Nausea (14) · Vomiting (14) · Postoperative Nausea and Vomiting (10) · Lymphoma, Non-Hodgkin (5) · Lymphoma (4) · Burkitt Lymphoma (3) · Hodgkin Disease (3) · Leukemia, Hairy Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (3) · Leukemia, Myelomonocytic, Chronic (3) · Leukemia, Neutrophilic, Chronic (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3)
Dartmouth-Hitchcock Medical Center (2) · Northwell Health (2) · Vanderbilt University (2) · Australasian Leukaemia and Lymphoma Group (1) · Barbara Ann Karmanos Cancer Institute (1) · Drexel University (1) · Drexel University College of Medicine (1) · Duke University (1) · Gachon University Gil Medical Center (1) · Gynecologic Oncology Group (1) · Hubei Cancer Hospital (1) · Kyungpook National University Hospital (1) · M.D. Anderson Cancer Center (1) · Main Line Health (1) · Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (1)
United States (22) · China (2) · South Korea (2) · Belgium (1) · Japan (1)
Andrew Grigg, Professor (1) · Ashish Sinha, MD (1) · Barbara A. Murphy, MD (1) · Betty Chan (1) · Christopher Choi, DDS (1) · Dmitri Chamchad, MD (1) · Donald A Mahler, M.D. (1) · Donald A Mahler, MD (1) · Franco Muggia, MD (1) · Guang Han, MD (1) · Jay Horrow, MD (1) · Jonathan P Wanderer, MD, MPhil (1) · Joseph Bubalo, PharmD (1) · Kai Schoenhage, MD (1) · Maria A Michaelis, MD (1)
PMID 22260216, PMID 33001556, PMID 38323173
P30CA022453 (2), P30CA014089 (1), R01DA027031 (1), U10CA101165 (1)